
Join to View Full Profile
4805 Ne GlisanSte 11N-1Portland, OR 97213
Phone+1 503-215-5696
Fax+1 503-215-5695
Dr. Sanborn is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Sanborn is Medical Director of the Thoracic Oncology Program at Providence Cancer Institute, and Medical Director of the Phase I Clinical Trials Program at Earle A. Chiles Research Institute, a division of Providence. She is a Full Member of the Earle A. Chiles Research Institute at Providence Cancer Institute. She is board-certified in medical oncology and internal medicine, and serves as a member of the Institutional Review Board of Providence Portland Medical Center.
Dr. Sanborn completed her medical degree and hematology and medical oncology fellowship at Oregon Health & Science University. She attended the University of Illinois at Chicago for her residency in internal medicine.
Dr. Sanborn is a member of several professional organizations, including the American Society of Clinical Oncology, the International Association for the Study of Lung Cancer, the American Lung Association Medical Advisory Workgroup, the Southwest Oncology Group Thoracic Working Group, and the Hoosier Cancer Research Network Thoracic Clinical Trial Working Group.
Education & Training
Oregon Health & Science University (OHSU Health)Fellowship, Hematology and Medical Oncology, 2002 - 2005
University of Illinois College of Medicine at ChicagoResidency, Internal Medicine, 1999 - 2002
Oregon Health and Science University School of MedicineClass of 1999
Cornell CollegeBA, Biology, 1995
Certifications & Licensure
OR State Medical License 2005 - 2025
IL State Medical License 1999 - 2002
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
Clinical Trials
- Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer Start of enrollment: 2008 Jan 01
- Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer Start of enrollment: 2010 Oct 14
- Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma. Start of enrollment: 2011 Jul 01
Publications & Presentations
PubMed
- Efficacy and safety of garsorasib in patients with KRAS G12C-mutated advanced pancreatic cancer.Noboru Yamamoto, Dong Yan, Vinod Ganju, Xinfang Hou, Hongming Pan
British Journal of Cancer. 2026-02-01 - Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients With Select Solid Tumors.Jong Chul Park, David Berz, Manish R Sharma, Jyoti Malhotra, Anthony W Tolcher
Cancer Research Communications. 2026-01-27 - Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer.Melissa L Johnson, Egbert F Smit, Enriqueta Felip, Suresh S Ramalingam, Myung-Ju Ahn
Journal of Clinical Oncology. 2025-12-10
Lectures
- Targeted Onocology Cased-Based Peer Perspectives on Targeted Therapy and IO for Lung CancerTacoma, WA (Virtual Meeting) - 8/2020
- Case-Based Peer Perspectives in EGFR-Mutated NSCLC and in Small Cell Lung CancerTacoma, WA (Virtual Meeting) - 6/2020
- Maximizing the Benefits of Targeted TherapiesChicago, IL (ASCO Virtual Meeting) - 5/2020
Press Mentions
“All Patients Should Have Their Tumor Sequenced at Least Once”June 13th, 2022
TKI plus SBRT Tops TKI Alone for Oligometastatic EGFRm NSCLCJune 8th, 2020
Heat Biologics Announces First Patient Dosed in the First Phase 1 Trial of HS-130December 16th, 2019
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









